Metformin and Propranolol Interaction: Synergistic | Peptide Database

Phenylpiracetam enhances memory consolidation and retrieval through AMPA receptor modulation and increased dopaminergic signaling. Clinical studies in patients with cognitive impairment from organic brain disease and cerebrovascular conditions have shown statistically significant improvements in memory test scores. The dopaminergic and noradrenergic activity of phenylpiracetam provides a clean stimulant effect that enhances sustained attention, task motivation, and mental stamina. This distinguishes it from piracetam and most other racetams, which lack meaningful stimulant properties. Phenylpiracetam improves physical endurance, reduces perception of effort, and enhances exercise tolerance. These effects were significant enough to earn it a place on the WADA prohibited substances list. Athletes have reported improved stamina and recovery during competition. Phenylpiracetam was approved in Russia for asthenia and chronic fatigue states of various origins. Clinical trials demonstrated improvements in subjective energy, motivation, and capacity for sustained mental and physical work in patients with post-infectious, cerebrovascular, and post-traumatic asthenia. Approved for cognitive deficits associated with cerebrovascular disease. Patients showed improvements in memory, attention, and overall cognitive functioning, along with reductions in depression and anxiety. Phenylpiracetam has demonstrated anticonvulsant properties in preclinical models and was included in the Russian clinical indication for adjunctive treatment of convulsive conditions. Developed for Soviet cosmonauts to withstand extreme cold. Animal studies confirm that phenylpiracetam significantly increases resistance to hypothermia. This property is unique among the racetam family and has potential applications for military, aerospace, and extreme sports contexts. The dopaminergic activity of phenylpiracetam provides mood-elevating effects that may benefit individuals with depression, particularly anhedonic subtypes. This remains investigational, with supporting evidence primarily from clinical observations and the known pharmacological profile rather than large-scale controlled trials.

Join others researching Ovagen — share findings, ask questions, and learn from real experiences Ovagen is a Khavinson bioregulator tripeptide (EDL) with primary effects on the liver and gastrointestinal tract. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it reduces long-term liver fibrosis and protects the GI mucosal layer from antibiotics, environmental toxins, and chemotherapy. Like other bioregulators, Ovagen crosses cell and nuclear membranes to directly regulate DNA transcription patterns with tissue-specific effects. Ovagen works through epigenetic regulation by crossing cell and nuclear membranes to directly regulate DNA structure and transcription patterns. It is transported into cells via POT family transporters (PEPT1, PEPT2) that specifically handle di- and tripeptides, explaining its precise tissue targeting. The peptide has tissue-specific effects on liver and GI tract, reducing fibrosis and protecting mucosal integrity.